Enclomiphene citrate is a Selective Estrogen Receptor Modulator (SERM) that works by stimulating your body's own testosterone production — rather than replacing testosterone from an external source. It targets the hypothalamus and pituitary gland, the control center of the male hormonal system, and signals them to produce more of the hormones that drive testicular testosterone production.
The result is elevated testosterone through your body's natural pathways, with one critical advantage over traditional TRT: enclomiphene does not suppress spermatogenesis. Men who want to maintain fertility, preserve their natural hormonal axis, or avoid the lifelong commitment of injectable testosterone have an alternative. One oral tablet. No needles. No HPG axis suppression.
Enclomiphene is particularly well-suited for men with secondary hypogonadism — where the testes are capable of producing testosterone but the brain's signaling is insufficient.
Includes ongoing provider care & support
Lab review & dose adjustment · Platform access
Enclomiphene clinical data demonstrates meaningful testosterone restoration with preservation of the HPG axis.
Rather than introducing testosterone directly, enclomiphene tells your body's own control system to produce more. The difference matters — both medically and for your long-term hormonal health.
Enclomiphene is a trans-isomer of clomiphene and acts as a Selective Estrogen Receptor Modulator (SERM). At the hypothalamus and anterior pituitary, it blocks estrogen receptors — preventing estrogen from delivering its normal feedback signal that tells these glands to reduce hormone output. With that feedback signal blocked, the hypothalamus increases GnRH (gonadotropin-releasing hormone) secretion, which is the upstream trigger for the entire testosterone production cascade.
Increased GnRH from the hypothalamus stimulates the pituitary to release more LH (luteinizing hormone) and FSH (follicle-stimulating hormone). LH acts directly on the Leydig cells of the testes — the cells responsible for testosterone production — stimulating them to synthesize and release more testosterone. FSH simultaneously supports Sertoli cell function and spermatogenesis. Both signals are elevated, restoring the full endocrine cascade.
The key distinction from TRT: your testes are producing the testosterone, not receiving it from outside. This means the HPG axis remains active and functional, spermatogenesis continues, and testicular volume is maintained. If enclomiphene is stopped, the natural system resumes its prior state. There is no suppression to recover from — a meaningful advantage for men who may want to cycle protocols or plan for fertility in the future.
Pricing
One flat rate. Physician supervision, oral medication, and ongoing support included.
Month-to-month. Full flexibility.
$66/mo · Save $38 vs monthly.
$59/mo · Save $120 vs monthly.
$49/mo · Save $360 vs monthly.
Includes: physician consultation · oral medication · ongoing provider support · free shipping
LH and FSH begin rising within the first week of daily dosing. The testes respond by increasing testosterone synthesis. Symptom changes at this stage are subtle as hormone levels are still stabilizing.
Total testosterone continues to rise as the LH signal to the Leydig cells becomes established. Many men begin noticing improvements in energy, libido, and mood during this window. Lab work at week 4–6 confirms hormone response.
With consistent daily dosing, testosterone levels stabilize in the target range. Energy, body composition, libido, and mood improvements consolidate. Follow-up labs confirm you are in range and guide any dose adjustment.
Long-term enclomiphene use continues to support testosterone in the normal range. Because the mechanism is hormonal stimulation rather than replacement, the system remains active and responsive throughout treatment.
Enclomiphene is generally well tolerated at therapeutic doses. Labs before starting and follow-up monitoring are required.
Mild headache and nausea can occur when starting, typically resolving within the first 1–2 weeks. Some men notice mood changes during the initial weeks as estrogen receptor signaling adjusts. These effects are generally transient and mild at the doses used for testosterone stimulation.
SERMs as a class carry a small risk of visual disturbances, including blurred vision or light sensitivity. This is a class-level effect seen primarily with clomiphene and at higher doses. If you experience any visual changes while on enclomiphene, discontinue and contact your provider immediately. Visual changes are reversible on discontinuation in most cases.
Men with primary hypogonadism (where the testes themselves are dysfunctional) will not respond meaningfully to enclomiphene, as stimulating LH and FSH cannot restore function in non-functional testes. Confirmed primary hypogonadism requires direct testosterone replacement. Lab work distinguishes these two diagnoses before prescribing.
Enclomiphene requires baseline testosterone, LH, FSH, estradiol, and standard metabolic labs before initiation. Follow-up labs at 4–6 weeks assess hormone response and guide dose adjustment. Men with a history of liver disease, thromboembolic events, or hormone-sensitive conditions should discuss risks with their provider before starting. All Obsidian Genetics prescriptions include a full health history review by a licensed provider.
Off-Label Use Notice: Enclomiphene citrate is not FDA-approved for the treatment of male hypogonadism or testosterone deficiency. It is prescribed off-label based on clinical trial data and established use in reproductive endocrinology. Obsidian Genetics prescriptions are issued following a clinical review of lab results and health history by a licensed physician.
Not Medical Advice: The content on this page is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Results are not guaranteed and individual outcomes depend on baseline hormone levels and the underlying cause of testosterone deficiency.
Citations: Enclomiphene efficacy and fertility preservation: Wiehle RD et al., Fertility and Sterility (2014). Comparative data vs. testosterone gel: Taylor F & Levine L, Journal of Sexual Medicine (2010). HPG axis mechanism: standard endocrinology reference (Boron & Boulpaep, Medical Physiology).
©2024 Obsidian Genetics. All rights reserved. Obsidian Genetics is a telehealth platform connecting patients with licensed providers.